Rosenblum Silverman Sutton S F Inc. CA Lowers Stock Position in Merck & Co., Inc. (NYSE:MRK)

Rosenblum Silverman Sutton S F Inc. CA cut its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 3.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,016 shares of the company’s stock after selling 135 shares during the period. Rosenblum Silverman Sutton S F Inc. CA’s holdings in Merck & Co., Inc. were worth $337,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. JJJ Advisors Inc. acquired a new stake in shares of Merck & Co., Inc. during the second quarter worth $27,000. PRW Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $41,000. Aspire Private Capital LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $55,000. Thor Advisors LLC acquired a new stake in shares of Merck & Co., Inc. during the first quarter worth $69,000. Finally, Contravisory Investment Management Inc. lifted its holdings in shares of Merck & Co., Inc. by 19.7% during the second quarter. Contravisory Investment Management Inc. now owns 858 shares of the company’s stock worth $72,000 after purchasing an additional 141 shares during the period. Institutional investors and hedge funds own 75.34% of the company’s stock.

Several equities research analysts recently weighed in on MRK shares. Argus increased their price target on Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Bank of America set a $97.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, July 11th. Citigroup increased their price target on Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, June 21st. They noted that the move was a valuation call. Morgan Stanley increased their price target on Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, June 21st. Finally, Mizuho reaffirmed a “buy” rating and set a $97.00 price target on shares of Merck & Co., Inc. in a report on Monday, August 5th. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $91.07.

Merck & Co., Inc. stock traded down $1.32 during midday trading on Wednesday, reaching $84.76. The company’s stock had a trading volume of 262,546 shares, compared to its average volume of 10,840,713. Merck & Co., Inc. has a fifty-two week low of $66.10 and a fifty-two week high of $87.07. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 0.82. The company’s 50 day simple moving average is $83.39. The company has a market capitalization of $218.96 billion, a price-to-earnings ratio of 19.48, a PEG ratio of 1.74 and a beta of 0.56.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.14. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The company had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. During the same quarter last year, the company earned $1.06 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 12.4% compared to the same quarter last year. As a group, equities analysts predict that Merck & Co., Inc. will post 4.91 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 2.60%. The ex-dividend date is Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 50.69%.

In other news, CFO Robert M. Davis sold 216,718 shares of Merck & Co., Inc. stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $85.43, for a total transaction of $18,514,218.74. Following the completion of the transaction, the chief financial officer now owns 354,378 shares of the company’s stock, valued at approximately $30,274,512.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Richard R. Deluca sold 6,427 shares of Merck & Co., Inc. stock in a transaction on Friday, August 9th. The stock was sold at an average price of $85.09, for a total value of $546,873.43. Following the transaction, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by company insiders.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: What does it mean to hold a stock in street name?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.